-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Guanlan Pharmaceutical
Today (April 2), Gen House announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration has recently accepted the clinical trial application for its Class 1 new drug GH35.
Screenshot source: CDE official website
GH35 is a KRAS G12C inhibitor developed by Qinhao Pharmaceutical.
Studies have shown that KRAS gene mutations exist in a variety of tumors, among which G12C mutations are mainly found in lung cancer, colorectal cancer and pancreatic cancer.
Note: The original text has been deleted